Clinical Trial

Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the safety and potential efficacy of the EN-374 treatment regimen and identify a dose level for further evaluation in participants with x-linked chronic granulomatous disease. The main questions it aims to answer are: * safety of the EN-374 treatment regimen * effect of the EN-374 treatment regimen on the production of functional neutrophils with NADPH oxidase activity
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2025-03-10; most recent amendment 2026-04-24.
Status change: Not Yet Recruiting → Recruiting 2025-08-05
Trial Details
NCT Number NCT06876363
Lead Sponsor Ensoma
Conditions X-Linked Chronic Granulomatous Disease
Enrollment 15 participants
Start Date 2025-08-05
Primary Completion 2027-12 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-27